BiotechTube

Necitumumab-Gemcitabine-Cisplatin

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Squamous Cell Lung Cancer

Conditions

Squamous Cell Lung Cancer

Trial Timeline

May 29, 2018 → Sep 26, 2019

NCT ID
NCT03574818

About Necitumumab-Gemcitabine-Cisplatin

Necitumumab-Gemcitabine-Cisplatin is a phase 2 stage product being developed by Eli Lilly for Squamous Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03574818. Target conditions include Squamous Cell Lung Cancer.

What happened to similar drugs?

4 of 20 similar drugs in Squamous Cell Lung Cancer were approved

Approved (4) Terminated (2) Active (14)
✅Pembrolizumab + Carboplatin + PaclitaxelMerckApproved
✅erlotinib [Tarceva]RocheApproved
✅erlotinib [Tarceva]RocheApproved
✅Platinum-based chemotherapy + Bevacizumab [Avastin]RocheApproved
🔄CT-P51 + EU-approved KeytrudaCelltrionPhase 3
🔄Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
🔄Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03574818Phase 2Terminated

Competing Products

20 competing products in Squamous Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
14
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
Cemiplimab + CetuximabEli LillyPhase 2
42
BB-401Benitec BiopharmaPhase 2
25
Ramucirumab + PaclitaxelEli LillyPhase 2
35
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
CT-P51 + EU-approved KeytrudaCelltrionPhase 3
47
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
39
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
47
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
39
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3
44
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
32
Avelumab + enfortumab vedotinAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
avelumab + Bempegaldesleukin + talazoparib + enzalutamideAstellas PharmaPhase 1/2
24
Drug Combination TherapySun PharmaceuticalPhase 2
42
Lenvatinib + Pembrolizumab + Docetaxel + Capecitabine + Paclitaxel + Cetuximab + LenvatinibEisaiPhase 2
35